Methods and devices for collecting and storing clinical samples for genetic analysis

• US 6,168,922 B1
• Filed: 02/22/1999
• Issued: 01/02/2001
• Est. Priority Date: 04/09/1997
• Status: Expired due to Term

• Current Assignee: Schleicher & Schuell Inc.
• Original Assignee: Schleicher & Schuell Inc.
• Inventors: King, Thomas H., Harvey, Michael A., Kremer, Richard D., Burghoff, Robert L.
• Primary Examiner(s): Witz, Jean C.
• Application Number:
  US09/255,151
• Time in Patent Office: 680 Days
• Field of Search: 435/2, 435/6, 435/372
• US Class Current: 435/6.16
• CPC Class Codes: B01J 2219/00639 the compounds being trapped in or bound to a porous medium
• CPC Class Codes: B01J 2219/00722 Nucleotides
• CPC Class Codes: C12N 15/1003 Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
• CPC Class Codes: C12Q 1/6806 Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay C12Q1/6804 takes precedence
• CPC Class Codes: C12Q 2527/127 the enzyme inhibitor or activator used
• CPC Class Codes: C12Q 2565/625 being a nucleic acid test strip device, e.g. dipsticks, strips, tapes, CD plates
• CPC Class Codes: C40B 40/06 Libraries containing nucleotides or polynucleotides, or derivatives thereof

Abstract

The present invention relates to devices and methods for the collection, storage, and purification of nucleic acids, such as DNA or RNA, from fluid samples for subsequent genetic characterization, primarily by conventional amplification methods. The present invention can be used to collect, store, or purify nucleic acids either from a biological source other than untreated whole blood, the biological source having naturally occurring nucleic acid amplification inhibitors present, (including either a buccal swab, cerebrospinal fluid, feces, lymphatic fluid, a plasma sample, a saliva sample, a serum sample, urine, or a suspension of cells or viruses), or from a treated whole blood source that has naturally occurring nucleic acid amplification inhibitors present, as well as added blood stabilization components that also inhibit nucleic acid amplification. More importantly, these nucleic acids can be released after collection or storage in a manner that enables them to be amplified by conventional techniques such as polymerase chain reaction. In particular, an absorbent material that does not bind nucleic acids irreversibly is impregnated with a chaotropic salt. A biological source sample is contacted with the impregnated absorbent material. Any nucleic acids present in the biological source can be either eluted or resolubilized off the absorbent material.

Claims

1. A device for storing and purifying nucleic acids from a biological source other than untreated whole blood, the biological source having naturally occurring nucleic acid amplification inhibitors present, comprising an absorbent material that does not bind irreversibly to nucleic acids, a chaotropic salt impregnated about the absorbent material, nucleic acids from the biological source releasably bound to the absorbent in an amplifiable form, the amplification inhibitors being bound to the adsorbent such that resolubilization does not occur by releasing the nucleic acids from the adsorbent.

2. The device of claim 1 wherein the biological source comprises a bodily fluid or a tissue.

3. The device of claim 2 wherein the bodily fluid comprises a buccal swab, cerebrospinal fluid, feces, lymphatic fluid, a plasma sample, a saliva sample, a serum sample, urine, or a suspension of cells or viruses.

4. The device of claim 3 wherein the nucleic acid amplification inhibitor is a protein.

5. The device of claim 1 wherein the absorbent material comprises cellulosics, porous glasses, woven porous polymers, or non-woven porous polymers.

6. The device of claim 1 wherein the chaotropic salt comprises an iodide salt or a guanidium salt.

7. The device of claim 1 wherein the guanidinium salt comprises guanidine hydrochloride, guanidine isothiocyanate, or guanidine thiocyanate.

8. A method for collecting and storing nucleic acids from a biological source other than untreated whole blood, the biological source having naturally occurring nucleic acid amplification inhibitors present comprising:

a) contacting a biological source with an absorbent material that does not bind to nucleic acids and which has a chaotropic salt impregnated about the absorbent material; and

b) allowing the nucleic acids and the amplification inhibitors of the biological source to be absorbed onto or dried on the absorbent material for storage.

9. The method of claim 8 wherein the biological source comprises a bodily fluid or a tissue.

10. The method of claim 9 wherein the bodily fluid comprises a buccal swab, a saliva sample, a serum sample, a plasma sample, a feces sample, a urine sample, spinal fluid sample, a sputum sample, lymphatic fluid, or a suspension of cells or viruses.

11. The method of claim 10 wherein the nucleic acid amplification inhibitor is a protein.

12. The method of claim 8 wherein the absorbent material comprises cellulosics, woven porous polymers, or non-woven porous polymers.

13. The method of claim 8 wherein the chaotropic salt comprises an iodide salt or a guanidium salt.

14. The method of claim 13 wherein the guanidinium salt comprises guanidine hydrochloride, guanidine isothiocyanate, or guanidine thiocyanate.

15. A method for collecting, storing, and purifying nucleic acids from a biological source other than untreated whole blood, the biological source having naturally occurring nucleic acid amplification inhibitors present, such that the nucleic acids can be amplified comprising:

(a) contacting a biological source with an absorbent material that does not bind to nucleic acids and which has a chaotropic salt impregnated about the absorbent material;

(b) allowing the nucleic acids and the amplification inhibitors of the biological source to be absorbed onto or dried on the absorbent material for storage; and

(c) eluting the nucleic acids from the dried biological source into a solution that can be used in a nucleic acid amplification process, whereby the amplification inhibitors remain bound to the adsorbent.

16. The method of claim 15 wherein the biological source comprises a bodily fluid or a tissue.

17. The method of claim 16 wherein the bodily fluid comprises a buccal swab, a saliva sample, a serum sample, a plasma sample, a fecal sample, a urine sample, spinal fluid sample, a sputum sample, lymphatic fluid, or a suspension of cells or viruses.

18. The method of claim 17 wherein the nucleic acid amplification inhibitor is a protein.

19. The method of claim 15 wherein the absorbent material comprises cellulosics, woven porous polymers, or non-woven porous polymers.

20. The method of claim 15 wherein the chaotropic salt comprises an iodide salt or a guanidinium salt.

21. The method of claim 15 wherein the guanidinium salt comprises guanidine hydrochloride, guanidine isothiocyanate, or guanidine thiocyanate.

22. A method for collecting, storing, and purifying nucleic acids from a biological source other than untreated whole blood, the biological source having naturally occurring nucleic acid amplification inhibitors present, such that the nucleic acids can be amplified comprising:

(a) contacting a biological source with an absorbent material that does not bind to nucleic acids and which has a chaotropic salt impregnated about the absorbent material;

(b) allowing the nucleic acids and the amplification inhibitors of the biological source to be absorbed onto or dried on the absorbent material for storage; and

(c) adding the absorbent material into a nucleic acid re-solubilizing solution, whereby the nucleic acids elute into the solution, but the amplification inhibitors remain bound to the adsorbent.

23. The method of claim 22 wherein the biological source comprises a bodily fluid or a tissue.

24. The method of claim 23 wherein the bodily fluid comprises a buccal swab, a saliva sample, a serum sample, a plasma sample, a feces sample, a urine sample, a spinal fluid sample, a sputum sample, lymphatic fluid, or a suspension of cells or viruses.

25. The method of claim 22 wherein the nucleic acid amplification inhibitor is a protein.

26. The method of claim 22 wherein the absorbent material comprises cellulosics, woven porous polymers, or non-woven porous polymers.

27. The method of claim 22 wherein the chaotropic salt comprises an iodide salt or a guanidium salt.

28. The method of claim 27 wherein the guanidinium salt comprises guanidine hydrochloride, guanidine isothiocyanate, or guanidine thiocyanate.

29. A device for storing and purifying nucleic acids from a treated whole blood source that has naturally occurring nucleic acid amplification inhibitors present, as well as added blood stabilization components that also inhibit nucleic acid amplification, comprising an absorbent material that does not bind irreversibly to nucleic acids, a chaotropic salt impregnated about the absorbent material, nucleic acids from the treated whole blood source releasably bound to the absorbent in an amplifiable form, and the amplification inhibitors from the biological source being bound to the adsorbent such that resolubilization does not occur by releasing the nucleic acids from the adsorbent.

30. The device of claim 29 wherein the added blood stabilization component comprises a chelator.

31. The device of claim 29 wherein the added blood stabilization component comprises a anticoagulant.

32. The device of claim 29 wherein the absorbent material comprises cellulosics, porous glasses, woven porous polymers, or non-woven porous polymers.

33. The device of claim 29 wherein the chaotropic salt comprises an iodide salt or a guanidium salt.

34. The device of claim 33 wherein the guanidinium salt comprises guanidine hydrochloride, guanidine isothiocyanate, or guanidine thiocyanate.